Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TERIPARATIDE vs CHRONULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Treatment of postmenopausal women with osteoporosis at high risk for fracture,Treatment of men with primary or hypogonadal osteoporosis at high risk for fracture,Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
20 mcg subcutaneously once daily.
10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.
Terminal half-life approximately 1 hour following subcutaneous administration; clinical duration limited by rapid clearance, necessitating once-daily dosing.
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Teriparatide is metabolized via non-specific proteolytic degradation in the liver and peripheral tissues. No specific cytochrome P450 enzymes are involved.
Not absorbed systemically; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Primarily hepatic metabolism via nonspecific proteolytic enzymes; no significant renal or biliary excretion; minimal unchanged drug in urine or feces.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Approximately 40-50% bound to plasma proteins, primarily albumin.
Negligible (<5%), primarily to albumin.
Approximately 0.2-0.3 L/kg, indicating distribution largely confined to extracellular fluid and bone.
Approximately 0.25 L/kg; distributes mainly into extracellular fluid.
Subcutaneous: approximately 95% bioavailability.
Oral: poorly absorbed; <3% reaches systemic circulation as intact lactulose; the remainder is metabolized by colonic bacteria.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not recommended in severe renal impairment (Cr Cl ≤30 m L/min) due to lack of data.
No dose adjustment required for renal impairment; caution in severe renal impairment due to electrolyte disturbances.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C).
No adjustment needed; used in hepatic encephalopathy at higher doses.
Not approved for use in pediatric patients; safety and efficacy not established.
Infants: 2.5-5 m L orally once daily; Children 1-5 years: 5-10 m L once daily; Children 6-12 years: 10-15 m L once daily; Adolescents: 15-30 m L once daily; adjust based on response.
No dose adjustment required; clinical studies included patients >65 years with no significant differences in efficacy or safety.
Start at low end of dosing range (10-15 m L once daily) due to increased risk of electrolyte imbalance and dehydration; monitor fluid/electrolyte status.
Increased risk of osteosarcoma in animal studies. Avoid use in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior radiation therapy involving the skeleton, or bone metastases.
None.
Risk of osteosarcoma (see black box warning),Orthostatic hypotension may occur, especially with initial doses,Hypercalcemia may occur; monitor serum calcium,Use with caution in patients with active urolithiasis,May increase serum uric acid
Electrolyte disturbances (e.g., hypernatremia, hypokalemia) with prolonged use or high doses,Diarrhea may cause fluid and electrolyte loss,Risk of colonic distention or fecal impaction,Use caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (contains galactose and lactose)
Paget's disease of bone,Unexplained elevations of alkaline phosphatase,Open epiphyses (pediatric patients),Prior radiation therapy involving the skeleton,Bone metastases or history of skeletal malignancies,Metabolic bone diseases other than osteoporosis,Pregnancy and lactation,Hypersensitivity to teriparatide or any component
Patients with galactosemia,Intestinal obstruction,Known hypersensitivity to lactulose
No specific food interactions. However, ensure adequate dietary calcium and vitamin D intake (e.g., dairy products, green leafy vegetables, fortified foods) to support the anabolic effect. Avoid excessive sodium, protein, and caffeine, which may increase calcium excretion. Do not take calcium supplements within 2 hours of teriparatide injection if instructed to take them separately, though generally they can be taken together.
No specific food interactions, but avoid concurrent use with other laxatives. Ensure adequate fluid intake to reduce risk of hypernatremia.
Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal skeletal effects.
Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not conducted. Based on lack of systemic absorption, risk to fetus is low across all trimesters.
No human data; teriparatide likely excreted in milk in low amounts. M/P ratio unknown. Recommend caution or avoid breastfeeding.
Lactulose is not absorbed orally; therefore, excretion into breast milk is negligible. Considered compatible with breastfeeding; no M/P ratio available due to lack of systemic absorption.
No dose adjustment recommended based on pharmacokinetic changes; however, use only if potential benefit justifies risk.
No dose adjustment required during pregnancy. Pharmacokinetics of lactulose are unchanged due to lack of systemic absorption. Use standard dosing for constipation (15-30 m L daily, titrated to effect).
Teriparatide is a recombinant human parathyroid hormone analog used for osteoporosis. It is the only anabolic agent that stimulates new bone formation. Administer as a subcutaneous injection in the thigh or abdomen. Rotate injection sites. Do not use in patients with Paget's disease, unexplained alkaline phosphatase elevation, prior radiation therapy to the skeleton, or bone metastases. Maximum duration of therapy is 24 months over a patient's lifetime due to an increased risk of osteosarcoma in rats. Monitor serum calcium levels at baseline and periodically; may cause transient hypercalcemia 4-6 hours after dosing. Contraindicated in hypercalcemia, pregnancy, and lactation.
Chronulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Onset of action for constipation is 24-48 hours; monitor for electrolyte disturbances (hypernatremia) with prolonged use. Do not use with other laxatives in acute abdomen. For hepatic encephalopathy, titrate to 2-3 soft stools daily.
Store teriparatide in the refrigerator at 2-8°C (36-46°F) and never freeze. Protect from light and do not use if the solution is cloudy, colored, or contains particles.,Inject once daily using the provided pen device. Administer at the same time each day, preferably in the morning, into the thigh or abdomen. Rotate injection sites to avoid lipodystrophy.,Sit or lie down during the first few doses if you experience dizziness or rapid heartbeat, as teriparatide may cause orthostatic hypotension. Stand up slowly.,Do not use teriparatide for more than 24 months total over your lifetime. Inform your doctor if you have Paget's disease, a history of radiation therapy, or bone cancer.,Contact your doctor if you have persistent nausea, vomiting, constipation, muscle weakness, or confusion, as these may be signs of hypercalcemia.,Take calcium and vitamin D supplements as recommended by your doctor, typically 1000 mg calcium and 800 IU vitamin D daily, to support bone formation.
May take 24-48 hours to produce a bowel movement; do not use if you have abdominal pain, nausea, or vomiting.,Mix with fruit juice, milk, or water to improve taste.,Store at room temperature; do not freeze.,Report excessive diarrhea or electrolyte imbalance symptoms (muscle cramps, weakness).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TERIPARATIDE vs CHRONULAC, answered by our medical review team.
TERIPARATIDE is a Parathyroid Hormone Analog that works by Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.. CHRONULAC is a Osmotic Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TERIPARATIDE and CHRONULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TERIPARATIDE is: 20 mcg subcutaneously once daily.. The standard adult dose of CHRONULAC is: 10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TERIPARATIDE and CHRONULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TERIPARATIDE is classified as Category A/B. Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal ske. CHRONULAC is classified as Category C. Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.